首页> 外文期刊>Scandinavian journal of clinical and laboratory investigation. >Enzymatic assays for creatinine: Time for action
【24h】

Enzymatic assays for creatinine: Time for action

机译:肌酐的酶法测定:作用时间

获取原文
获取原文并翻译 | 示例
           

摘要

Estimation of glomerular filtration rate (eGFR) on the basis of serum creatinine concentration measurements using equations is critical to ongoing global public health efforts to improve the diagnosis and treatment of chronic kidney disease. There is now ongoing activity to promote world-wide standardization of methods to measure creatinine concentrations, together with the introduction of a revised eGFR equation appropriate for use with standardized creatinine methods. Standardization of calibration, i.e. implementation of calibration traceable to higher-order reference measurement procedures and reference materials, does not, however, correct for analytical interferences of field methods (non-specificity bias). To account for the sensitivity of alkaline picrate-based methods to non-creatinine chromogens, some manufacturers have adjusted the calibration to minimize the pseudo-creatinine contribution of plasma proteins, thereby producing results more closely aligned with the reference method (isotope dilution-mass spectrometry), but this strategy makes the assumption that the non-creatinine chromogen interference is constant among samples, which is an oversimplification. Thus, analytical non-specificity for substances found in individual patient samples affects the accuracy of eGFR computed from serum creatinine concentrations for any alkaline picrate method, including the so-called "compensated" Jaffe methods. Using assays that are more specific for serum creatinine, such as those based on enzymatic reactions, may provide more reliable eGFR values. Supporting the choice of more specific assays by clinical laboratories'is one of the main tasks of our profession in achieving the ultimate clinical goal, which is to routinely report an accurate eGFR in all pertinent clinical situations.
机译:使用方程式根据血清肌酐浓度测量值估算肾小球滤过率(eGFR),对于正在进行的全球公共卫生工作以改善慢性肾脏病的诊断和治疗至关重要。现在正在开展活动,以促进全世界范围内测量肌酐浓度的方法的标准化,同时引入适用于标准化肌酐方法的修订版eGFR方程。校准的标准化,即可追溯到高阶参考测量程序和参考材料的校准的实施,不能纠正现场方法的分析干扰(非特异性偏差)。为了考虑基于碱性苦味酸盐的方法对非肌酸酐色原的敏感性,一些制造商已调整标定,以最大程度地降低血浆蛋白的假肌酸酐贡献,从而产生与参考方法更接近的结果(同位素稀释质谱法) ),但是此策略假设样品中的非肌酐色原干扰是恒定的,这过于简单了。因此,对于单个患者样品中发现的物质而言,分析性非特异性会影响从血清肌酐浓度针对任何碱性苦味苦味酸盐方法(包括所谓的“补偿” Jaffe方法)计算的eGFR的准确性。使用对血清肌酐更具特异性的测定(例如基于酶促反应的测定)可能会提供更可靠的eGFR值。支持临床实验室选择更具体的测定方法是我们实现最终临床目标的主要任务之一,该目标是在所有相关临床情况下常规报告准确的eGFR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号